ReviewExpert review of cardiovascular therapy2011
Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles.
Review in Expert review of cardiovascular therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Cardio-microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C-MIC II open-label randomized controlled trial.European journal of heart failure · 2025Trial
- Topical vascular organoid therapy promotes microvascular regeneration and functional recovery in porcine ischemic cardiomyopathy.Stem cell reports · 2026Article
- Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study.ESC heart failure · 2025Article
- GPC3-mediated metabolic rewiring of diabetic mesenchymal stromal cells enhances their cardioprotective functions via PKM2 activation.iScience · 2024Article
- The Implications of Aging on Vascular Health.International journal of molecular sciences · 2024Review
- EstablishingMolecules (Basel, Switzerland) · 2024Article
- The Impact of Coronary Artery Disease on Outcomes in Patients With Peripartum Cardiomyopathy.Cureus · 2024Article
- Review
- A Vegfc-Emilin2a-Cxcl8a Signaling Axis Required for Zebrafish Cardiac Regeneration.Circulation research · 2022Article
- Modulation of VEGFA Signaling During Heart Regeneration in Zebrafish.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Diabetes impairs cardioprotective function of endothelial progenitor cell-derived extracellular vesicles via H3K9Ac inhibition.Theranostics · 2022Article
- HIF in the heart: development, metabolism, ischemia, and atherosclerosis.The Journal of clinical investigation · 2021Review
- Biologics and their delivery systems: Trends in myocardial infarction.Advanced drug delivery reviews · 2021Review
- Role of melatonin in the angiogenesis potential; highlights on the cardiovascular disease.Journal of inflammation (London, England) · 2021Review
- PTEN inhibitor improves vascular remodeling and cardiac function after myocardial infarction through PI3k/Akt/VEGF signaling pathway.Molecular medicine (Cambridge, Mass.) · 2020Article
- Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.Molecular therapy. Methods & clinical development · 2020Article
- Coronary Revascularization During Heart Regeneration Is Regulated by Epicardial and Endocardial Cues and Forms a Scaffold for Cardiomyocyte Repopulation.Developmental cell · 2019Article
- Tricyclic antidepressant amitriptyline inhibits autophagic flux and prevents tube formation in vascular endothelial cells.Basic & clinical pharmacology & toxicology · 2019Article
- Successful rebuilding after disaster, even in the heart, starts with infrastructure.Journal of thoracic disease · 2018Article
- Opioids: Modulators of angiogenesis in wound healing and cancer.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A significant percentage of patients have coronary artery disease that is too advanced or diffuse for percutaneous or surgical intervention. Therapeutic angiogenesis is a treatment modality to induce vessel formation that is being developed for patients with advanced coronary disease not amenable to currently available interventions. A number of approaches to induce coronary collateralization are being developed. These include gene, protein, cellular and miRNA modalities, each of which have advantages and disadvantages. At this time, no modality has emerged as the single clear choice, and combination therapies may provide synergistic benefits. However, there have been a number of recent studies advancing our knowledge as to how we can refine procollateralizing treatments. In this article, we will examine some recent successes and future obstacles in the effort to bring therapeutic angiogenesis to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.